Streetbeat News

Products Services

MA

Mastercard's joint venture in China has received approval to begin domestic payments processing, allowing Mastercard cardholders in China to have seamless payment experiences both domestically and internationally.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 1:42 pm

DRTS

Alpha Tau Medical Ltd. (NASDAQ:DRTS, DRTSW) has submitted a pre-market approval request to Japan's PMDA for its Alpha DaRT therapy for recurrent head and neck cancer. The submission follows successful clinical trials in Japan that met safety and efficacy endpoints. Alpha Tau and HekaBio are in talks with biopharmaceutical companies for a commercial partnership in Japan. The therapy targets solid tumor cancers post-radiation treatment, with over 10,000 new cases annually in Japan.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 1:31 pm

AZN

AstraZeneca has launched Evinova, a health-tech business aimed at accelerating innovation in life sciences, optimizing clinical trial design, and improving health outcomes. Evinova will operate within AstraZeneca, leveraging digital health solutions that are evidence-led and science-based. The company has established strategic collaborations with CROs Parexel and Fortrea, and is working with Accenture and Amazon Web Services to expand its digital products' reach. Evinova's solutions include a unified trial solution, study design and planning, and portfolio management. The digital health market is expected to grow significantly, and Evinova's solutions are designed to reduce healthcare costs and enhance patient experiences.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 1:27 pm

AAPL

Apple Inc. (AAPL) devices, including iPhones and iPads, remain susceptible to the Flipper Zero hack, which exploits a vulnerability in the Bluetooth Low-Energy pairing process, causing devices to crash. Despite the issue being known since 2020, Apple has not yet released a fix in its latest iOS updates. Users' temporary solution is to disable Bluetooth, which limits device functionality.

Portfolio Pulse from Rounak Jain

November 20, 2023 | 1:25 pm

FRSX

Eye-Net, a subsidiary of Foresight Autonomous Holdings (FRSX), has been selected by the European Software République consortium to participate in developing road safety solutions. The consortium comprises major companies like Dassault Systèmes, Eviden, Orange, Renault Group, STMicroelectronics, and Thales.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 1:22 pm

WLDS

Wearable Devices has successfully completed the first phase of deployment testing for an OEM specializing in extended reality glasses. This marks a significant milestone for the company, potentially leading to further development and commercialization opportunities.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 1:21 pm

MA

Mastercard Inc (NYSE:MA) has partnered with Feedzai to enhance its capabilities in combating crypto fraud using AI. The collaboration will integrate Feedzai with Mastercard's CipherTrace Armade platform, allowing banks to monitor transactions from over 6,000 crypto exchanges for fraudulent and suspicious activities. This initiative is part of Mastercard's effort to normalize crypto as a financial asset, subject to traditional regulatory frameworks. The company's data indicates that crypto transaction fraud is five times higher than that of fiat transactions. Despite this move, a Mastercard executive recently criticized the use of central bank digital currencies (CBDCs), citing a lack of justification for their widespread adoption. Mastercard's stock (MA) saw a slight increase of 0.12% to $400.80 in premarket trading.

Portfolio Pulse from Lekha Gupta

November 20, 2023 | 1:16 pm

JNJ

Janssen, part of Johnson & Johnson, submitted a supplemental Biologics License Application to the FDA for RYBREVANT combined with chemotherapy to treat EGFR-mutated non-small cell lung cancer post-osimertinib. The submission is based on Phase 3 MARIPOSA-2 study results, which showed improved progression-free survival compared to chemotherapy alone. The study was presented at the ESMO 2023 Congress and published in Annals of Oncology. RYBREVANT previously received accelerated FDA approval for NSCLC with EGFR exon 20 insertion mutations.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 1:15 pm

ELWS

Earlyworks Co., Ltd. (NASDAQ:ELWS) has signed an MOU with Pole to Win Vietnam to form an alliance leveraging Earlyworks' private blockchain technology, Grid Ledger System (GLS), to provide blockchain quality assurance services. The alliance aims to offer low-cost verification solutions to the Web 3.0 industry, addressing the high costs and resource pressures of in-house verification. Earlyworks' CEO, Satoshi Kobayashi, sees this as a cornerstone for expansion in the quality assurance market and a means to improve blockchain product standards.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 1:14 pm

BCLI

BrainStorm Cell Therapeutics has scheduled an in-person meeting with the FDA on December 6 to discuss a confirmatory Phase 3 trial for NurOwn, its treatment for ALS. The company aims to seek a Special Protocol Assessment (SPA) for the trial.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 1:12 pm